Literature DB >> 1907221

Experimental chemotherapy of Trypanosoma cruzi infection: persistence of parasite antigens and positive serology in parasitologically cured mice.

S G Andrade1, L A Freitas, S Peyrol, A R Pimentel, M Sadigursky.   

Abstract

Mice infected with Trypanosoma cruzi, but parasitologically cured after specific chemotherapy, continued to exhibit positive indirect immunofluorescence serological tests 3-6 months after the therapy. Treatment of trypanosome antigens with monospecific antisera produced in rabbits, and examination by immunoelectron-microscopy following peroxidase labelling disclosed the presence of membrane deposits in cell processes in the spleens of the mice. Similar deposits were observed in the external membranes of T. cruzi amastigotes in the spleens of acutely infected mice, but not in normal control mice. No reaction occurred in tissues not previously treated with the monospecific anti-T. cruzi serum. Positive cells in treated and cured mice, as well as in the not cured or untreated control mice, were located in germinal centres of the splenic white pulp and presented long and branching cytoplasmic processes, which are indicative of dendritic cells of the lymphoid follicles of the spleen.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1907221      PMCID: PMC2393081     

Source DB:  PubMed          Journal:  Bull World Health Organ        ISSN: 0042-9686            Impact factor:   9.408


  17 in total

1.  Enzyme-labeled antibodies: preparation and application for the localization of antigens.

Authors:  P K Nakane; G B Pierce
Journal:  J Histochem Cytochem       Date:  1966-12       Impact factor: 2.479

2.  Comparative studies of drug susceptibility of five strains of Trypanosoma cruzi in vivo and in vitro.

Authors:  R A Neal; J van Bueren
Journal:  Trans R Soc Trop Med Hyg       Date:  1988       Impact factor: 2.184

3.  [Treatment of Chagas' disease].

Authors:  W Apt
Journal:  Rev Med Chil       Date:  1985-02       Impact factor: 0.553

4.  Trypanosoma cruzi antigens detected by immunoelectron microscopy in the spleen of mice serologically positive but parasitologically cured by chemotherapy. (Preliminary report).

Authors:  S G Andrade; L A Freitas; S Peyrol; A R Pimentel; M Sadigursky
Journal:  Rev Soc Bras Med Trop       Date:  1988 Jan-Mar       Impact factor: 1.581

5.  A nitroimidazole-thiadiazole derivative with curative action in experimental Trypanosoma cruzi infections.

Authors:  L S Filardi; Z Brener
Journal:  Ann Trop Med Parasitol       Date:  1982-06

6.  The maintenance and regulation of serum antibody levels: evidence indicating a role for antigen retained in lymphoid follicles.

Authors:  J G Tew; T Mandel
Journal:  J Immunol       Date:  1978-03       Impact factor: 5.422

7.  The early stages of absorption of injected horseradish peroxidase in the proximal tubules of mouse kidney: ultrastructural cytochemistry by a new technique.

Authors:  R C Graham; M J Karnovsky
Journal:  J Histochem Cytochem       Date:  1966-04       Impact factor: 2.479

8.  Binding of labelled antigens and immune complexes to macrophages and dendritic cells in cryostat sections of normal mouse spleen.

Authors:  N Van Rooijen
Journal:  Acta Morphol Neerl Scand       Date:  1978-05

9.  Evaluation of chemotherapy with benznidazole and nifurtimox in mice infected with Trypanosoma cruzi strains of different types.

Authors:  S G Andrade; J B Magalhães; A L Pontes
Journal:  Bull World Health Organ       Date:  1985       Impact factor: 9.408

10.  Therapeutic action of MK-436 (2,5-nitroimidazole) on Trypanosoma cruzi infections in mice: a parasitological, serological, histopathological, and ultrastructural study.

Authors:  S G Andrade; R C Silva; C M Santiago; L A Freitas
Journal:  Bull World Health Organ       Date:  1987       Impact factor: 9.408

View more
  9 in total

1.  Lychnopholide in Poly(d,l-Lactide)-Block-Polyethylene Glycol Nanocapsules Cures Infection with a Drug-Resistant Trypanosoma cruzi Strain at Acute and Chronic Phases.

Authors:  Renata Tupinambá Branquinho; Carlos Geraldo Campos de Mello; Maykon Tavares Oliveira; Levi Eduardo Soares Reis; Paula Mello de Abreu Vieira; Dênia Antunes Saúde-Guimarães; Vanessa Carla Furtado Mosqueira; Marta de Lana
Journal:  Antimicrob Agents Chemother       Date:  2020-03-24       Impact factor: 5.191

2.  Changes in Trypanosoma cruzi-specific immune responses after treatment: surrogate markers of treatment efficacy.

Authors:  Susana A Laucella; Damián Pérez Mazliah; Graciela Bertocchi; María G Alvarez; Gretchen Cooley; Rodolfo Viotti; María C Albareda; Bruno Lococo; Miriam Postan; Alejandro Armenti; Rick L Tarleton
Journal:  Clin Infect Dis       Date:  2009-12-01       Impact factor: 9.079

3.  Posttherapeutic cure criteria in Chagas' disease: conventional serology followed by supplementary serological, parasitological, and molecular tests.

Authors:  G F Machado-de-Assis; A R Silva; V A L Do Bem; M T Bahia; O A Martins-Filho; J C P Dias; P Albajar-Viñas; R M Torres; M Lana
Journal:  Clin Vaccine Immunol       Date:  2012-06-27

Review 4.  Trypanocidal drugs for chronic asymptomatic Trypanosoma cruzi infection.

Authors:  Juan Carlos Villar; Juan Guillermo Perez; Olga Lucia Cortes; Adelina Riarte; Micah Pepper; Jose Antonio Marin-Neto; Gordon H Guyatt
Journal:  Cochrane Database Syst Rev       Date:  2014-05-27

5.  Benznidazole treatment following acute Trypanosoma cruzi infection triggers CD8+ T-cell expansion and promotes resistance to reinfection.

Authors:  Bianca Perdigão Olivieri; Vinícius Cotta-De-Almeida; Tania Araújo-Jorge
Journal:  Antimicrob Agents Chemother       Date:  2002-12       Impact factor: 5.191

6.  Use of the EIE-recombinant-Chagas-biomanguinhos kit to monitor cure of human Chagas' disease.

Authors:  Edimilson D Silva; Valéria R A Pereira; Juliana A S Gomes; Virgínia Maria B Lorena; Joaquim R Cançado; Antonio G P Ferreira; Marco Aurélio Krieger; Samuel Goldenberg; Rodrigo Correa-Oliveira; Yara M Gomes
Journal:  J Clin Lab Anal       Date:  2002       Impact factor: 2.352

7.  Serological evaluation of specific-antibody levels in patients treated for chronic Chagas' disease.

Authors:  Olga Sánchez Negrette; Fernando J Sánchez Valdéz; Carlos D Lacunza; María Fernanda García Bustos; María Celia Mora; Alejandro D Uncos; Miguel Angel Basombrío
Journal:  Clin Vaccine Immunol       Date:  2007-12-05

8.  Experimental benznidazole treatment of Trypanosoma cruzi II strains isolated from children of the Jequitinhonha Valley, Minas Gerais, Brazil, with Chagas disease.

Authors:  Jaquelline Carla Valamiel de Oliveira-Silva; Girley Francisco Machado-de-Assis; Maykon Tavares Oliveira; Nívia Carolina Noguieira Paiva; Márcio Sobreira Silva Araújo; Cláudia Martins Carneiro; Olindo Assis Martins-Filho; Helen Rodrigues Martins; Marta de Lana
Journal:  Mem Inst Oswaldo Cruz       Date:  2015-01-23       Impact factor: 2.743

9.  Interleukin-12 enhances in vivo parasiticidal effect of benznidazole during acute experimental infection with a naturally drug-resistant strain of Trypanosoma cruzi.

Authors:  V Michailowsky; S M Murta; L Carvalho-Oliveira; M E Pereira; L R Ferreira; Z Brener; A J Romanha; R T Gazzinelli
Journal:  Antimicrob Agents Chemother       Date:  1998-10       Impact factor: 5.191

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.